The Piro Lito Lab: Publications

Print
Print

Xue, Y; Martelotto, L; Baslan, T; Vides, A; Solomon, M; Mai, T; Chaudhary, N; Riely,G; Li, B; Scott, K; Cechhi,F; DeStanchina, E; Schwartz, S; Nanjangud, G; Berger, M; Nilsson, J; Lowe, S; Reis-Filho, J; Rosen, N and Lito, P; An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nature Medicine, 2017 Jul 17. doi: 10.1038/nm.4369.

Lito, P*; Solomon, M; Li, L; Hansen, R and Rosen*, N; Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science, 2016, 10.1126/science.aad6204. *Co-corresponding authors

Xue,Y and Lito, P; Predicting MEK inhibitor response in lung cancer: a proper signature is required. Clin Cancer Res. 2016 Dec 6. pii: clincanres.2576.2016.

Lito, P; Saborowski, A; Yue J; Solomon, M; Joseph, E; Saborowski, M; Fellmann, C; Ohara, K; Morikami, K; Miura, T; Lukas, C; Ishii, N; Lowe, S and Rosen, N; Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell, 2014, 25(5):697-710.

Lito, P; Mets, BD; Kleff, S; O’Reilly, S; Maher, VM and McCormick, JJ; Sprouty 2 is necessary for tumor formation by HRas-transformed human fibroblasts. Journal of Biological Chemistry, 283, 2002-2009, 2008. PMCID: PMC2613613

Lito, P; Pantanowitz, L; Marroti, J; Bower, M; Campbell, V; Aboulafia, D and Dezube, B.; Neuroendocrine tumors in patients infected with HIV. American Journal of the Medical Sciences, 337(1), 1-4, 2009

Lito, P; Mets, BD; Appledorn, DM; Maher, VM and McCormick, JJ; Sprouty 2 prevents apoptosis induced by DNA damage. Journal of Biological Chemistry, 284, 848-854, 2009. PMCID: PMC2613613

Lito, P; Pratilas, CA; Joseph CW; Tadi, M; Halilovic, E; Zubrowski, M; Huang, A; Wong, WL; Callahan, MK; Merghoub, T; Wolchok, JD; de Stanchina, E; Chandarlapaty, S; Poulikakos, PI; Fagin, JA and Rosen, N; Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell, 2012 Nov 13;22(5):668-82. PMCID:PMC3713778

Lito, P; Rosen, N and Solit, D; Tumor adaptation and resistance to RAF inhibitors. Nature Medicine, 2013 Nov;19(11).

Chung, S; Kim, S; Park, J; Chung, Y; Lito, P; Feldstein, J; Hu, W; Patel, M; Kim, M; Melnick, A; Rosen, N; Tallman, M; Park, C; and Abdel-Wahab, O.; BRAFV600E Mutations are Present in Hematopoietic Stem Cells from Hairy Cell Leukemia Patients Suggesting an Immature Cell Origin. Science Translational Medicine, 6(238) 2014

Lito, P; Saborowski, A; Yue J; Solomon, M; Joseph, E; Saborowski, M; Fellmann, C; Ohara, K; Morikami, K; Miura, T; Lukas, C; Ishii, N; Lowe, S and Rosen, N; Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell, 2014, 25(5):697-710.

Naidoo, J; Santos-Zabala, M; Iyriboz, T; Woo, K; Sima, C; Fiore, J; Kris, M; Riely, G; Lito, P; Iqbal, A; Veach, S; Smith-Marrone, S; Sarkaria, I; Krug, L; Rudin, C; Travis, W; Rekhtman, N; Pietanza, M; Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer, 2016 Jan 21. pii: S1525-7304(16)0006-1.

Lito, P*; Solomon, M; Li, L; Hansen, R and Rosen*, N; Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science, 2016, 10.1126/science.aad6204. *Co-corresponding authors